DERM News and Press, Journey Medical Corporation From 10/31/23

SCOTTSDALE, Ariz., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the selling and marketing of FDA-approved prescription pharmaceutical product...

Shares of Journey Medical Corporation (NASDAQ: DERM) traded at a new 52-week high today and are currently trading at $3.36. So far today, approximately 18,363 shares have been exchanged, as compared to an average 30-day volume of 30,093 shares. Journey Medical Corporation focuses on the devel...

Study demonstrated systemic exposure of DFD-29 was significantly lower than that of Solodyn (105 mg) Data presented at 43rd Annual Fall Clinical Dermatology Conference New Drug Application submission to FDA for DFD-29 anticipated in the fourth quarter of 2023 SCOTTSDALE, A...

2023-10-18 10:11:35 ET More on Journey Medical Journey Medical director Paley buys 15k shares - filing Journey Medical announces exclusive license agreement with Maruho For further details see: Journey Medical says Smith buys 33K shares in co

2023-10-11 10:52:01 ET More on Journey Medical Journey Medical Q2 2023 Earnings Call Transcript Journey Medical announces exclusive license agreement with Maruho Seeking Alpha’s Quant Rating on Journey Medical Historical earnings data for Journey Medic...

2023-09-06 12:53:35 ET Gainers: NeuBase Therapeutics ( NBSE ) +124% . Palisade Bio ( PALI ) +113% . Power REIT ( PW ) +45% . AeroVironment ( AVAV ) +26% . Theratechnologies ( THTX ) +27% . iCoreConnect ( ICCT ) +20% ....

2023-09-06 09:11:11 ET More on Journey Medical, Fortress Biotech Journey Medical Corporation ( DERM ) Q2 2023 Earnings Call Transcript Stocks To Watch: Investors Prep For Inflation Data And Q2 Earnings Rush Journey Medical stock rallies 20% on Phase 3 studies upd...

SCOTTSDALE, Ariz., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (&#...

Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023 Positive topline results from two Phase 3 clinical trials evaluating DFD-29 demonstrated achievement of co-primary and all secondary endpoints versus pla...

2023-08-12 10:15:17 ET Journey Medical Corporation (DERM) Q2 2023 Earnings Conference Call August 8 2023 4:00 PM ET Company Participants Matt Blazei - CoreIR Claude Maraoui - Co-Founder, President and Chief Executive Officer Joseph Benesch - Interim Chief Financi...